Your browser doesn't support javascript.
loading
Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases.
Yang, Penghui; Luo, Qun; Wang, Xinlu; Fang, Qi; Fu, Zhenli; Li, Jia; Lai, Yunxin; Chen, Xiaobo; Xu, Xin; Peng, Xiaomin; Hu, Kongzhen; Nie, Xiaowei; Liu, Shaoyu; Zhang, Jinhe; Li, Junqi; Shen, Chenyou; Gu, Yingying; Liu, Jianping; Chen, Jingyu; Zhong, Nanshan; Su, Jin.
Affiliation
  • Yang P; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Luo Q; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Wang X; Department of Nuclear Medicine, and.
  • Fang Q; Department of Nuclear Medicine, and.
  • Fu Z; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Li J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Lai Y; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Chen X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Xu X; Department of Thoracic Surgery/Oncology, State Key Laboratory, and National Clinical Research Center for Respiratory Disease.
  • Peng X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Hu K; Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Nie X; Jiangsu Key Laboratory of Organ Transplantation, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
  • Liu S; Department of Nuclear Medicine, and.
  • Zhang J; Department of Nuclear Medicine, General Hospital of Southern Theatre Command of People's Liberation Army of China, Guangzhou, China; and.
  • Li J; Shenzhen International Institute for Biomedical Research, Shenzhen, Guangdong, China.
  • Shen C; Jiangsu Key Laboratory of Organ Transplantation, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
  • Gu Y; Respiratory Pathology Center, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Liu J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Chen J; Jiangsu Key Laboratory of Organ Transplantation, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
  • Zhong N; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
  • Su J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health.
Am J Respir Crit Care Med ; 207(2): 160-172, 2023 01 15.
Article in En | MEDLINE | ID: mdl-35984444
ABSTRACT
Rationale Sustained activation of lung fibroblasts and the resulting oversynthesis of the extracellular matrix are detrimental events for patients with interstitial lung diseases (ILDs). Lung biopsy is a primary evaluation technique for the fibrotic status of ILDs, and is also a major risk factor for triggering acute deterioration. Fibroblast activation protein (FAP) is a long-known surface biomarker of activated fibroblasts, but its expression pattern and diagnostic implications in ILDs are poorly defined.

Objectives:

The present study aims to comprehensively investigate whether the expression intensity of FAP could be used as a potential readout to estimate or measure the amounts of activated fibroblasts in ILD lungs quantitatively.

Methods:

FAP expression in human primary lung fibroblasts as well as in clinical lung specimens was first tested using multiple experimental methods, including real-time quantitative PCR (qPCR), Western blot, immunofluorescence staining, deep learning measurement of whole slide immunohistochemistry, as well as single-cell sequencing. In addition, FAP-targeted positron emission tomography/computed tomography imaging PET/CT was applied to various types of patients with ILD, and the correlation between the uptake of FAP tracer and pulmonary function parameters was analyzed. Measurements and Main

Results:

Here, it was revealed, for the first time, FAP expression was upregulated significantly in the early phase of lung fibroblast activation event in response to a low dose of profibrotic cytokine. Single-cell sequencing data further indicate that nearly all FAP-positive cells in ILD lungs were collagen-producing fibroblasts. Immunohistochemical analysis validated that FAP expression level was closely correlated with the abundance of fibroblastic foci on human lung biopsy sections from patients with ILDs. We found that the total standard uptake value (SUV) of FAP inhibitor (FAPI) PET (SUVtotal) was significantly related to lung function decline in patients with ILD.

Conclusions:

Our results strongly support that in vitro and in vivo detection of FAP can assess the profibrotic activity of ILDs, which may aid in early diagnosis and the selection of an appropriate therapeutic window.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lung Diseases, Interstitial / Positron Emission Tomography Computed Tomography Type of study: Risk_factors_studies / Screening_studies Limits: Humans Language: En Journal: Am J Respir Crit Care Med Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lung Diseases, Interstitial / Positron Emission Tomography Computed Tomography Type of study: Risk_factors_studies / Screening_studies Limits: Humans Language: En Journal: Am J Respir Crit Care Med Year: 2023 Document type: Article